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TLRs	may	contribute	to	the	progression	of	rheumatoid	arthritis	through	recognition	of	microbial	or	host-
derived	ligands	found	in	arthritic	joints.	Here,	we	show	that	TLR2	and	TLR4,	but	not	TLR9,	are	involved	in	
the	pathogenesis	of	autoimmune	arthritis	and	play	distinct	roles	in	the	regulation	of	T	cells	and	cytokines.	
We	investigated	the	involvement	of	TLR2,	TLR4,	and	TLR9	in	the	progression	of	arthritis	using	IL-1	receptor	
antagonist–knockout	(IL1rn–/–)	mice,	which	spontaneously	develop	an	autoimmune	T	cell–mediated	arthritis.	
Spontaneous	onset	of	arthritis	was	dependent	on	TLR	activation	by	microbial	flora,	as	germ-free	mice	did	
not	develop	arthritis.	Clinical	and	histopathological	evaluation	of	IL1rn–/–Tlr2–/–	mice	revealed	more	severe	
arthritis,	characterized	by	reduced	suppressive	function	of	Tregs	and	substantially	increased	IFN-γ	produc-
tion	by	T	cells.	IL1rn–/–Tlr4–/–	mice	were,	in	contrast,	protected	against	severe	arthritis	and	had	markedly	lower	
numbers	of	Th17	cells	and	a	reduced	capacity	to	produce	IL-17.	A	lack	of	Tlr9	did	not	affect	the	progression	
of	arthritis.	While	any	therapeutic	intervention	targeting	TLR2	still	seems	complicated,	the	strict	position	of	
TLR4	upstream	of	a	number	of	pathogenic	cytokines	including	IL-17	provides	an	interesting	potential	thera-
peutic	target	for	rheumatoid	arthritis.
Introduction
RA is an autoimmune disease manifested by chronic inflammation 
and cartilage and bone destruction in multiple joints. Etiopathol-
ogy of RA has been subjected to intensive research, resulting in the 
knowledge that proinflammatory cytokines such as TNF-α, IL-1, 
and IL-17 as well as T and B lymphocytes are implicated in the 
pathogenesis of RA; however, it is still not clear which mechanisms 
are involved in the initiation and regulation of cytokine produc-
tion and lymphocyte activation.
The discovery of TLRs as essential components of the immune 
system has introduced new subjects to the field of research on the 
pathogenesis of autoimmune diseases. TLRs are primarily involved in 
innate immune response to microbial pathogens through recognition 
of conserved pathogen-associated molecular patterns (1); however, 
they also contribute to sterile inflammation by sensing the “danger 
signals,” i.e., endogenous molecules that are generated during tissue 
damage or inflammation (2–4). Activation of TLRs forms an impor-
tant bridge between innate and adaptive immunity by regulating the 
expression of costimulatory molecules on APCs to drive T cell activa-
tion and by creating a cytokine milieu to conduct the differentiation 
of T cells into the desired subset (5). In this context, activation of TLRs, 
for instance TLR4 and TLR9, is generally thought to induce a Th1 
response by driving IL-12 production by DCs (6–8); however, TLR2 
activation might induce a Th2-biased immune response, through 
production of IL-10 and IL-13, capable of aggravating experimental 
asthma (9–11). TLR2 has also been reported to trigger the prolifera-
tion of Tregs, which play a crucial role in the induction of tolerance to 
self antigens and protection against autoimmunity (12–14). On the 
other hand, direct TLR2 activation on Tregs may cause a transient 
loss of suppressive function in these cells, a mechanism aimed to pro-
mote the antibacterial immune response during infection (15, 16). 
Activation of TLR4 is important for the survival of pathogenic Th17 
cells through induction of IL-23 production by DCs (17); and, finally, 
TLR9 ligand CpG DNA inhibits CD4+CD25+ Treg–mediated suppres-
sion of the effector T cells (18, 19).
TLR ligands of microbial origin, such as bacterial DNA and pepti-
doglycans as well as Epstein-Barr virus, cytomegalovirus, and parvo-
virus, have repeatedly been found in joints of patients with RA, and 
several investigators have implicated bacterial or viral infections as 
initiating factors of the disease (20–24). In addition, the presence of 
endogenous TLR ligands such as fibronectin fragments and heat 
shock proteins, mainly activating TLR4 has been demonstrated 
in rheumatoid synovium (25–27). Since both microbial and host-
derived TLR ligands are present in arthritic joints, these receptors 
may contribute to the initiation as well as the chronic progression 
of RA. The idea of the involvement of TLRs in RA is supported by 
enhanced expression of TLR2, -3, -4, and -7 in synovial lining and 
elevated TLR2 expression in CD16+ blood monocytes and synovial 
macrophages of RA patients (28–31). Recently, Sacre et al. dem-
onstrated that the spontaneous production of proinflammatory 
cytokines and matrix metalloproteinases by RA synovial membrane 
cells is inhibited by overexpression of dominant-negative forms of 
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MyD88 and Mal, 2 essential adaptor molecules in signaling through 
TLR2 and TLR4 (32). This finding indicates that activation of TLR2 
or TLR4 or both by endogenous ligands drives the spontaneous pro-
duction of proinflammatory mediators by RA synovium.
In the present study, we investigated the involvement of TLR2, 
TLR4, and TLR9 in initiation and progression of arthritis using IL-1 
receptor antagonist–deficient (IL1rn–/–) mice, which spontaneously 
develop an autoimmune T cell–mediated arthritis due to excessive 
IL-1 signaling (33, 34). Development of arthritis in these mice relies 
on pathogenesis by TNF-α and IL-17 (34–36). Here, we report that 
TLR2 and TLR4, but not TLR9, are involved in the expression of 
autoimmune arthritis in IL1rn–/– model. IL1rn–/– mice lacking Tlr2 
showed an enhancement of clinical and histopathological scores 
of arthritis, whereas IL1rn–/–Tlr4–/– mice were protected against 
severe disease. We show that TLR2 downregulates the progression 
of arthritis through control of function of Tregs and regulation of 
IFN-γ–producing Th1 cells. TLR4, in contrast, contributes to more 
severe disease by modulating the Th17 cell population and IL-17 
production. Furthermore, we demonstrate that endogenous TLR4 
ligands are present in RA synovial fluid and drive the spontaneous 
production of cytokines in synovial tissue.
Results
Spontaneous onset of arthritis in IL1rn–/– mice is abrogated in the absence 
of microbial flora. IL1rn–/– mice develop spontaneous arthritis 
due to excessive IL-1 signaling. Since IL-1 receptor and TLRs 
share the signaling pathway, TLR activation might also func-
tion as a direct driving force behind the arthritis development in 
IL1rn–/– mice or could drive arthritis indirectly by inducing IL-1. 
To investigate the involvement of pathogen-associated molecu-
lar patterns delivered by microbial flora in the development of 
spontaneous arthritis in IL1rn–/– mice, germ-free IL1rn–/– mice 
were generated and observed for macroscopic manifestations of 
arthritis. Germ-free animals showed no signs of arthritis during 
20 weeks of follow-up, whereas age- and sex-matched non–germ-
free animals started to develop arthritis from the age of 5 weeks. 
At the age of 18 weeks, more than 80% of non–germ-free IL1rn–/– 
mice exhibited signs of arthritis, mainly in the hind ankle joints 
(Figure 1, A and B).
Monocontamination of germ-free animals with only 1 indig-
enous microflora, Lactobacillus bifidus (37), resulted in rapid onset 
of arthritis that reached incidence rate and severity scores compa-
rable to those in non–germ-free mice (Figure 1, A and B).
Figure 1
Effect of microbial status of IL1rn–/– mice on the development of arthritis and cytokine response to TCR and TLR stimulations. The incidence (A) 
and severity (B) of arthritis are completely abolished in germ-free (GF) IL1rn–/– mice, and infection of GF mice with Lactobacillus (arrows) leads 
to the same disease expression as in non–germ-free (NGF) animals. Arthritis severity was scored on a scale from 0 to 2 for each paw; n ≥ 6 per 
group. (C and D) Splenic lymphocytes (2 × 105) were stimulated with plate-coated anti-CD3 (2 μg/ml), Pam3Cys (100 ng/ml), or LPS (200 ng/ml) 
for 72 hours. IL-1 (C) and IL-17 (D) were measured using Luminex multianalyte technology (see Methods). Data are expressed as mean ± SD 
and are representative of 2 independent experiments.
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IL1rn–/– splenocytes exhibit an exaggerated response to TLR activation 
dependent on microbial status of mice. TLRs are the pivotal receptors 
that sense the presence of microbial agents. Therefore, we exam-
ined the effect of TLR activation on splenic lymphocytes of IL1rn–/– 
mice of both germ-free and non–germ-free status. As shown in 
Figure 1, C and D, stimulation of lymphocytes using anti-CD3 
(2 μg/ml) and TLR2 and TLR4 ligands (100 ng/ml Pam3Cys and 
200 ng/ml LPS, respectively) resulted in much higher production 
of IL-1β and IL-17 by IL1rn–deficient cells from non–germ-free 
mice than by splenocytes from non–germ-free BALB/c WT mice. 
Higher IL-17 production by CD3-stimulated IL1rn–/– lymphocytes 
was in line with data reported previously (35). The germ-free status 
of IL1rn–/– animals resulted in a moderate decrease in IL-1 and a 
notable disruption of IL-17 production upon CD3 as well as TLR2 
and TLR4 stimulation. IL-17 levels in germ-free mice were back to 
the WT levels, indicating that elevated production of this cytokine, 
which has been reported to be indispensable for the development 
of arthritis in IL1rn–/– mice (35), is completely dependent on previ-
ous confrontation with TLR agonists.
Acute stimulation of a single TLR results in aggravation of arthritis in 
IL1rn–/– mice. Activation of TLRs induces the expression of a broad 
range of proinflammatory mediators. To examine the effect of 
activation of a single TLR on the spontaneous onset and severity 
of arthritis, we treated 6-week-old IL1rn–/– mice without arthritis 
with a 1-shot i.p. injection of Pam3Cys (4 mg/kg body weight) or 
LPS (400 μg/kg). Both TLR ligands accelerated the initiation of 
the disease symptoms, causing the maximal disease incidence at 
the early age of 9 weeks (Figure 2A). The arthritis severity score was 
also strongly enhanced even 7 weeks after injection (Figure 2B). 
Although the final outcome was similar in Pam3Cys- and LPS-
treated groups, LPS accelerated the disease faster than Pam3Cys. 
LPS injection also caused arthritis in forepaws. These observations 
indicate that a single-shot acute triggering of either TLR2 or TLR4 
enhances the expression of arthritis in IL1rn–/– mice.
On histology, LPS dramatically aggravated cell influx, chondro-
cyte death, and cartilage and bone destruction (Figure 2C). Inflam-
mation was characterized by formation of villi and pannus tissue in 
synovium and the presence of both mononuclear and polymorpho-
nuclear cells in the infiltrate. Despite the increase in clinical disease 
score by Pam3Cys, no significant changes were found on histology.
TLR2, TLR4, and TLR9 are differentially involved in the development 
and progression of arthritis in IL1rn–/– mice. To study the contribution 
of distinct TLRs to the development and the progression of auto-
immune arthritis, we generated IL1rn–/– mice also lacking Tlr2, 
Tlr4, and Tlr9 genes on a BALB/c background. The development 
and progression of arthritis in IL1rn/Tlr double-deficient mice 
Figure 2
Effect of direct TLR2 and TLR4 stimulation on the development and pathogenesis of IL1rn–/– arthritis. Treatment of 5-week-old IL1rn–/– mice with 
1 i.p. injection of Pam3Cys (4 mg/kg body weight) or LPS (400 μg/kg body weight) increased the incidence (A) and the macroscopic severity 
score (B) of arthritis. (C) Histological analysis of the ankle joints at 13 weeks of age expressed as mean ± SEM on a scale from 0 to 3. All param-
eters were scored by 2 observers blinded to the experimental protocol; n = 9 mice per group. *P < 0.05 and **P < 0.01.
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were monitored over time and compared with those of age- and 
sex-matched IL1rn–/–Tlr+/+ littermates to avoid variations in arthri-
tis sensitivity based on differences in age, sex, and genetic back-
ground of the mice. These TLRs differentially contributed to the 
disease expression, since Tlr9 deficiency in IL1rn–/– mice did not 
affect the disease incidence and severity (data not shown). Tlr2–/– 
mice developed more severe progressive arthritis, whereas Tlr4 
deficiency protected IL1rn–/– mice from severe disease as described 
in the following sections.
Tlr2-deficient mice develop more severe arthritis than WT littermates. 
Although mice deficient for both IL1rn and Tlr2 had a slightly 
higher disease incidence compared with IL1rn–/–Tlr2+/+ littermates 
during the first weeks after onset, the incidence was similar at week 
15 (Figure 3A). Interestingly, Tlr2–/– mice developed more aggres-
sive arthritis that reached a macroscopic severity score approxi-
mately 70% higher than the score in Tlr2+/+ littermates (Figure 3B). 
On histological analysis of the ankle joints, Tlr2–/– mice showed 
substantially higher amounts of infiltrated inflammatory cells, 
more chondrocyte cell death, and depletion of matrix proteogly-
cans (PGs) in cartilage and significantly increased bone erosion 
compared with that in Tlr2+/+ counterparts (Figure 3, C and D). 
This suggests that TLR2 activation in IL1rn–/– animals induces an 
antiinflammatory mechanism to partly control the progression of 
arthritis and to protect the joint from extreme damage.
Tlr2 deficiency leads to a shift in T cell balance from Th2 and T regulatory 
cells toward pathogenic Th1 cells. TLR2 has been reported to modulate 
some T cell subsets, such as Th2 and Tregs (10, 15, 16, 38). There-
fore, we analyzed the mRNA expression of T box expressed in T cells 
(T-bet), GATA-binding protein 3 (GATA3), and Forkhead box P3 
(Foxp3) — specific markers for Th1, Th2, and Tregs, respectively — in 
synovial biopsies of moderately inflamed ankle joints from 15-week-old 
and in spleens of nonarthritic 6-week-old IL1rn–/–Tlr2+/+ and 
IL1rn–/–Tlr2–/– mice. Quantitative real-time PCR indicated a clear 
shift in the balance between the antiinflammatory Th2/Treg and 
the proinflammatory Th1 markers in favor of the Th1 subset in 
IL1rn–/–Tlr2–/– synovium and spleen (Figure 4, A and B). Splenic T 
Figure 3
Higher severity and increased histopathology of IL1rn–/– arthritis caused by Tlr2 deficiency. Percentage incidence (A) and severity score (B) of arthri-
tis in IL1rn–/–Tlr2+/+ mice compared with IL1rn–/–Tlr2–/– littermates. Severity was scored macroscopically on a scale of 0–2 for each paw; n > 20 mice 
per group. (C) Histological assessment of the ankle joints at 15 weeks (mean ± SEM) on a scale between 0 and 3 for each parameter; n = 14 mice 
per group. (D) Representative histological images of ankle joints. Cell influx and chondrocyte death were scored on H&E-stained (top row), and carti-
lage and bone damage (arrows) were scored on safranin O–stained (bottom row) tissue sections. PG depletion is apparent from loss of red staining. 
Original magnification, ×50 for H&E and ×100 for safranin O staining. B, bone; C, cartilage; JS, joint space; S, synovium. *P < 0.05 and **P < 0.01.
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cells from young IL1rn–/–Tlr2–/– mice just prior to the disease onset 
produced substantially higher levels of IFN-γ when stimulated 
with anti-CD3/anti-CD28 for 72 hours or with PMA/ionomycin 
for 5 hours (Figure 4C and data not shown). In addition, despite 
the similar Th17 cell subset on FACS analysis, IL1rn–/–Tlr2–/– T cells 
produced higher amounts of IL-17 upon these stimulations; how-
ever, this increase was not statistically significant (Figure 4D and 
data not shown). Next, we analyzed the Treg population in whole 
blood and spleen using FACS analysis. Although the percentage 
of CD4+CD25+Foxp3+ Tregs was not altered by Tlr2 deficiency, the 
Tregs from both blood and spleen of IL1rn–/–Tlr2–/– mice expressed 
significantly lower Foxp3 levels (Figure 4E). The expression of 
Figure 4
Influence of Tlr2 deficiency on various Th cell 
subsets and the expression of related cytokines. 
mRNA expression of T cell markers in inflamed 
synovium of the ankle joints (A) and spleens (B) 
of IL1rn–/–Tlr2–/– compared with IL1rn–/–Tlr2+/+ mice. 
Synovial biopsies were pooled from more than 5 
joints of 15-week-old mice, and spleens were from 
4 nonarthritic 6-week-old mice. mRNA expres-
sion was measured by quantitative PCR. Relative 
mRNA expression compared with the housekeep-
ing gene GAPDH (2-dCt × 1,000) is shown on the y 
axis. IFN-γ (C) and IL-17 (D) production by spleen 
and lymph node cells upon 72 hours stimulation 
with anti-CD3 (0.5 μg/0.2 ml/well) and anti-CD28 
(2 μg/ml), measured by Luminex; results are 
mean ± SEM from a representative experi-
ment with n > 4 mice per group. Protein expres-
sion of Foxp3 (E) and CD25 (F) on CD4+-gated 
CD25+Foxp3+ cells from whole blood and spleen 
of 15-week-old mice after correction for isotype-
matched IgG control; mean ± SEM of n = 3 from 
a representative experiment. (G and H) T cell sup-
pression assay on splenic cells of IL1rn–/–Tlr2+/+ 
and IL1rn–/–Tlr2–/– mice. (G) CD4+CD25– Teffs 
(50,000 cells/well) were stimulated with 1 μg/ml 
anti-CD3, 2 μg/ml concanavalin A, or 60 IU/ml IL-6 
(negative control) in the presence of 50,000/well 
irradiated CD4– cells as APCs. After 3 days, pro-
liferation was measured by [3H]thymidine incor-
poration. (H) For suppression assays, cells were 
incubated with anti-CD3 and APCs in the presence 
of titrated numbers of Tregs (CD4+CD25+). Percent 
suppression was calculated relative to the cultures 
without Tregs. Measurements were performed in 
triplicate, and values shown are mean ± SEM of 
4 mice per group. mRNA expression of TGF-β1 in 
noninflamed and inflamed ankle synovium (I) and 
spleen (J), measured by quantitative PCR. Rela-
tive mRNA expression compared with GAPDH is 
shown. *P < 0.05.
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CD25 on Tregs remained unchanged (Figure 4F). Tregs from 
IL1rn–/–Tlr2–/– mice had a functional defect in suppressing the anti-
CD3–stimulated proliferation of effector T cells (Teffs) at Treg/Teff 
ratios of 1:16 and 1:32 when compared with Tregs from IL1rn–/–
Tlr2+/+ matched littermates (Figure 4, G and H). Furthermore, the 
relative expression of the antiinflammatory mediator TGF-β1, 
which is abundantly secreted by Tregs, was dramatically lower in 
both noninflamed and inflamed synovial tissue and in spleens of 
Tlr2–/– mice (Figure 4, I and J). Reduced Foxp3 and TGF-β expres-
sion together with defective Treg function and enhanced IFN-γ pro-
duction in Tlr2–/– mice suggest a skewed T cell balance that might 
explain enhanced arthritis in IL1rn–/–Tlr2–/– mice.
Tlr4-deficient mice are protected against severe arthritis resulting 
from IL1rn gene deficiency. IL1rn–/–Tlr4+/+ and IL1rn–/–Tlr4–/– mice 
showed comparable disease incidence, indicating that the initia-
tion of arthritis is independent of TLR4 activation (Figure 5A); 
however, the macroscopic inflammation scores of IL1rn–/– mice 
lacking Tlr4 were greatly reduced compared with those of 
IL1rn–/–Tlr4+/+ littermates. The arthritis severity scores started 
to diverge from age 7–8 weeks, and the differences were most 
noticeable during the more-progressed chronic phase of the 
disease (13–15 weeks). Disease severity was reduced by 54% in 
Tlr4–/– mice at 15 weeks (Figure 5B).
Histological examination of the ankle joints revealed that Tlr4–/– 
animals developed less progressive joint damage, since microscop-
ic scores of inflammatory cell influx into the joint, chondrocyte 
death, cartilage PG depletion and destruction, and bone erosion 
were all significantly lower in IL1rn–/–Tlr4–/– mice compared with 
IL1rn–/–Tlr4+/+ littermates (Figure 5C). In line with reduced joint 
damage in Tlr4–/– mice, local mRNA expression of destruction-driv-
ing cytokines IL-23 and IL-17 was lower in synovial biopsies from 
IL1rn–/–Tlr4–/– compared with those of IL1rn–/–Tlr4+/+ mice with 
equal inflammation score of the dissected joints (Figure 5, D and 
E). The expression of T cell markers T-bet, GATA3, and Foxp3 was 
Figure 5
Lower severity and reduced histopathology of IL1rn–/– arthritis caused by Tlr4 deficiency. Similar incidence (A) and reduced severity (B) of arthritis 
in IL1rn–/–Tlr4–/– as compared with IL1rn–/–Tlr4+/+ littermates during the first 15 weeks of age. Severity was scored on a scale of 0 to 2 for each paw; 
n > 20 mice per group. (C) Histological assessment of the ankle joints at week 15 of age. Data are mean ± SEM (scale 0–3) of 14 mice per group. 
mRNA expression of IL-23p19 (D) and IL-17A (E) in synovial biopsies of the ankle joints of 15-week-old mice selected according to the degree 
of inflammation. mRNA expression was measured by quantitative real-time PCR. Relative expression compared with GAPDH (2-dCt × 10,000) 
is shown. (F) Representative images of the ankle joints. Cell influx and chondrocyte death (arrows) were scored on H&E-stained sections (top 
row), and cartilage and bone damage (arrows) were scored on safranin O–stained tissue sections (bottom row). Original magnification, ×100 for 
H&E and ×200 for safranin O staining. *P < 0.05 and ***P < 0.001.
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similar in the 2 groups. Furthermore, there was no difference in 
mRNA expression of IFN-γ or IL-10 on quantitative PCR. Figure 5F 
shows representative histological images of the ankle joints.
TLR4 regulates the number of Th17 cells and the production of IL-17 in 
IL1rn–/– mice. IL-17 has been described to play a crucial role in the 
spontaneous development of arthritis in IL1rn–/– mice (35). To clar-
ify the mechanism by which TLR4 regulated the disease expression, 
we studied the effect of Tlr4 deficiency on the number of IL-17–pro-
ducing T cells and on IL-17 production in IL1rn–/– mice. The per-
centage of CD4+ and CD4– Th17 cells was measured in both CD3+ 
splenocytes isolated using MACS technique and lymphocytes from 
popliteal and inguinal lymph nodes, before and after the onset of 
arthritis. FACS analysis revealed 50% reduction of CD4+IL-17+ Th17 
cells in both spleen and lymph nodes of Tlr4–/– mice, just before the 
expected onset of arthritis (5–6 weeks of age). The proportion of 
CD4– Th17 cells was also reduced, by approximately 70% (Figure 6, 
A and B). After the onset of arthritis (15 weeks of age), no clear dif-
ference in percentage of Th17 cells could be found; however, CD4+ 
Th17 cells in popliteal and inguinal lymph nodes draining the site of 
inflammation expressed markedly lower levels of IL-17 (183.8 ± 10.1 
in Tlr4+/+ vs. 107.0 ± 17.1 in Tlr4–/– mice; P = 0.0079).
To confirm the involvement of TLR4 activation in the regulation 
of IL-17 in IL1rn–/– mice, we measured the production of IL-17 pro-
tein by freshly isolated splenic and lymph node cells from 6-week-
old mice after ex vivo stimulation with PMA/ionomycin or with 
anti-CD3/anti-CD28. In agreement with FACS data, IL1rn–/–Tlr4–/– 
cells released significantly lower concentrations of IL-17 upon 
both stimulations compared with cells from their IL1rn–/–Tlr4+/+ 
littermates just before the initiation of arthritis (Figure 6C and 
data not shown). IL-10 and IFN-γ concentrations were not differ-
ent in these experiments. Lower IL-17 production by T cells from 
IL1rn–/–Tlr4–/– mice was also found in animals with established 
arthritis at 15 weeks of age, when the macroscopic severity score 
of arthritis was significantly lower in Tlr4–/– mice (data not shown). 
Involvement of TLR4 activation in regulating the Th17 subset of T 
cells and IL-17 production by these cells explained the finding that 
disease was less severe in Tlr4–/– mice.
Regulation of Th17 cell number and IL-17 production by TLR4 is medi-
ated through IL-1 and IL-23. IL-23 is a cytokine prominently involved 
in the survival of Th17 cells. IL-23 can be induced by TLR4 and 
has been shown to play a central role in the pathogenesis of spon-
taneous arthritis in IL1rn–/– mice through induction of IL-17 (36). 
To investigate whether modulation of Th17 cell number and 
IL-17 production in IL1rn–/– mice was mediated by IL-23, we stud-
ied the effect of TLR4 stimulation on the production of IL-23 by 
bone marrow–derived DCs from WT and IL1rn–/– mice. IL1rn gene 
deficiency did not interfere with the generation of CD11c+ DCs 
(75%–95%) and the maturation of these cells by LPS, as measured 
by MHC class II and CD86 expression (data not shown); however, 
IL1rn–/– DCs produced significantly more IL-23 than WT DCs 
upon stimulation with 100 ng/ml LPS for 24 hours (Figure 6D). 
Higher IL-23 production by APCs led to higher IL-17 production 
Figure 6
Decreased IL-17 in IL1rn–/–Tlr4–/– mice and IL-1–
mediated effects of TLR4 activation on IL-23/IL-17 
production. (A–D and F) Spleens and lymph 
nodes from 5- to 6-week-old mice without arthritis 
were isolated and disrupted. CD3+ T lymphocytes 
were isolated using magnetic beads (MACS). (A 
and B) Th17 FACS analysis following stimulation 
with PMA (50 ng/ml), ionomycin (1 μg/ml), and 
brefeldin (1 μl/ml) for 5 hours ; n = 4. (C) IL-17 pro-
duction by splenic and lymph node T cells upon 
stimulation with anti-CD3 (0.5 μg/0.2 ml/well) 
and anti-CD28 (2 μg/ml) for 72 hours; measured 
by Luminex; n ≥ 6. (D) TLR4 activation of bone 
marrow–derived DCs by 100 ng/ml LPS for 
24 hours resulted in higher IL-23 production in 
IL1rn–/– cells compared with BALB/c WT. IL-23 was 
measured by ELISA; n = 10. (E) TLR4 (200 ng/ml 
LPS) plus anti-CD3 (1 μg/ml) activation of splenic 
T cells leads to higher IL-1–mediated IL-17 pro-
duction in IL1rn–/– cells compared with WT cells, 
as measured by Luminex; n = 5. (F) Bone mar-
row–derived DCs from IL1rn–/–Tlr4–/– mice are not 
compromised in IL-23 production upon non-TLR4 
stimulations. DCs were stimulated with 100 ng/ml 
LPS, 100 ng/ml Pam3Cys, or a cocktail of IL-1β 
(25 ng/ml), TNF-α (25 ng/ml), IL-6 (100 ng/ml), 
and PGE2 (1 μg/ml) for 24 hours; n = 4 per group. 
Data are mean ± SEM. NRS, normal rabbit serum. 
*P < 0.05, **P < 0.01, and ***P < 0.001.
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by T cells in total splenocyte culture (APCs plus T cells) from non-
diseased IL1rn–/– mice stimulated with anti-CD3 in combination 
with LPS when compared with WT splenocyte culture (Figure 6E). 
IL-17 induction by TLR4 might also occur indirectly through IL-1, 
as IL-1 drives IL-23 production. Indeed, inhibition of IL-1 blocked 
the extremely high IL-17 production by IL1rn–/– T cells upon CD3/
LPS stimulation (Figure 6E). IL1rn–/–Tlr4–/– DCs were not compro-
mised in IL-23 production, as they produced IL-23 levels compara-
ble to those in IL1rn–/–Tlr4+/+ DCs when stimulated with non-TLR4 
proinflammatory modulators (Figure 6F). These data indicate that 
TLR4 controls the production of IL-17 by IL1rn–/– Th17 cells by 
inducing IL-23 and IL-1 production by IL1rn–/– APCs.
Presence of endogenous TLR4 ligands in RA joints drives the spontane-
ous production of cytokines by RA synovial tissue. To assess the clini-
cal relevance of TLR4 activation in RA patients, we investigated 
the presence of TLR4 ligands in synovial fluid from RA patients 
using HEK293 cells expressing TLR4. Cells were first tested for 
response to a number of proinflammatory mediators, including 
various TLR ligands. As shown in Figure 7A, HEK293-TLR4 cells 
produced IL-8 in a dose-dependent manner upon stimulation with 
LPS. Furthermore, they were highly stimulated by TNF-α but not 
by IL-1β and TLR2 and TLR7 ligands (Pam3Cys and Gardiqui-
mod, respectively). HEK293-TLR4 cells also produced low concen-
trations of IL-8 upon TLR3 stimulation by Poly(I:C) (Figure 7A). 
When incubated with RA synovial fluid in combination with a 
soluble TNF receptor (Enbrel) to block the response to putative 
TNF-α present in the samples, HEK293-TLR4 cells produced 
much higher concentrations of IL-8 compared with HEK293 cells 
without TLR4 (Figure 7B). This indicated the presence of endog-
enous TLR4 ligands capable of activating NF-κB in synovial fluid 
of RA patients, as these samples were previously shown to be endo-
toxin free in an assay based on the response of CHO-hTLR4-CD14 
cells in combination with polymyxin B (data not shown). Next, we 
examined the effect of TLR4 inhibition on spontaneous produc-
tion of cytokines by synovial tissue of RA patients. TLR4 antago-
nist partially inhibited the production of IL-1β, TNF-α, and IL-10 
by RA synovium in ex vivo cultures (Figure 7C), showing the 
involvement of TLR4 activation in this phenomenon.
Discussion
IL1rn–/– mice develop an autoimmune destructive arthritis that 
exhibits several characteristics of RA (33). Autoimmunity in these 
mice results from excessive IL-1 signaling due to the lack of natural 
IL-1 receptor antagonist. IL-1 contributes to autoantigen-specific 
T cell activation and antibody production through induction of 
CD40L and OX40 expression on T cells (36). IL-1 can also acti-
vate autoreactive CD4+ T cells by activating DCs (35). The T cell 
cytokines TNF-α and IL-17 are known to play crucial roles in IL1rn–/– 
arthritis (34, 35), and IL-23 has recently been demonstrated to be 
the link between IL-1 and IL-17 (36). Furthermore, T cells from 
IL1rn–/– mice have been reported to produce higher amounts of 
IFN-γ compared with WT T cells (34, 36). Despite the accumulating 
data on the complex cytokine network in this spontaneous model of 
arthritis, the initial trigger of cytokine production has not been elu-
cidated before. Our data indicate that a general proinflammatory 
event, e.g., sensing the microbial flora through TLRs, may send the 
first signal to induce IL-1 production and drive the T cell–mediated 
onset of arthritis in IL1rn–/– mice, since IL1rn–/– mice in germ-free 
conditions do not develop arthritis at all. In non–germ-free IL1rn–/– 
mice, a single-shot acute TLR2 or TLR4 activation is enough to 
overstate the incidence and the severity of arthritis. This appeared 
to be a general phenomenon caused by a strong pulse of proinflam-
matory cytokines and was also observed upon injection of synthetic 
TLR3 and TLR7 ligands [Poly(I:C) and loxoribine, respectively] (S. 
Abdollahi-Roodsaz, unpublished observations); however, only LPS 
enhanced long-term histological damage. Exceptionally, systemic 
injection of a TLR9 ligand (stimulatory CpG ODN1826) did not 
affect the expression of arthritis, probably because of the different 
cytokine profile induced by TLR9. Studies in IL1rn–/–Tlr–/– mice clar-
ified the role of distinct TLRs in fine-tuning the progression and 
chronicity of arthritis. TLR9 has been described to directly enhance 
the survival of activated murine CD4+ T cells and inhibit the sup-
Figure 7
TLR4-mediated stimulation of cytokine production by rheumatoid syno-
vial fluid and in synovial biopsies of RA patients. (A) HEK293-TLR4 
cells were stimulated with PMA, IL-1β, TNF-α, and various TLR ligands 
as indicated in Methods. Mean IL-8 concentrations (Luminex assay) 
of triplicates are shown. (B) HEK293 and HEK293-TLR4 cells were 
stimulated with synovial fluid of RA patients in the presence of a TNF-α 
blocker (Enbrel; 100 ng/ml) or remained unstimulated (medium con-
trol). IL-8 was measured in culture supernatants after 24 hours. Stimu-
lation index over medium control of each cell line is shown on the y 
axis; n = 7. Data are mean ± SEM. ***P < 0.001. (C) Synovial biopsies 
of RA patients were cultured ex vivo with or without TLR4 antagonist 
(10 μg/ml) for 24 hours. Experiments were performed in triplicate. The 
concentration of cytokines was measured using Luminex. Data are 
mean ± SEM from 7 RA patients.
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pressive properties of Tregs (18, 19, 39). Although TLR9 activation 
has recently been implicated in other autoimmune diseases such as 
multiple sclerosis, possibly through its activation by endogenous 
“danger signals” (40), Tlr9 deficiency did not affect the incidence 
and the severity of IL1rn–/– autoimmune arthritis. This suggests 
that there is no native TLR9 activation present in IL1rn–/– mice that 
could modulate the disease expression. Tlr2-deficient mice showed 
a higher disease incidence and developed a more aggressive form of 
arthritis. The observation that both application of a TLR2 ligand 
and Tlr2 deficiency result in aggravation of arthritis might seem 
contradictory at first glance; however, the expression pattern of 
TLR2 and the diverse nature of cytokines induced by TLR2 allow 
it to play a dual role depending on how and where it has been acti-
vated. Intraperitoneal injection of high-dose TLR2 ligand leads to 
the production of proinflammatory cytokines such as IL-1β, IL-6, 
and TNF-α, which are strong promoters of inflammation and 
are believed to be responsible for the aggravation of arthritis. On 
the other hand, TLR2 has been reported to induce a Th2-biased 
immune response capable of aggravating experimental asthma 
and to inhibit IFN-γ production by LPS-stimulated PBMCs (10, 11, 
41). In addition, Tlr2–/– mice have significantly lower number of 
Tregs due to lower IL-10 concentrations (12). Direct in vitro TLR2 
activation on Tregs, a situation mimicking bacterial infection, has 
recently been shown to induce the expansion of Tregs accompanied 
by a transient loss of function, which is recovered after removal of 
TLR2 ligand (15, 16).
Here, we describe a shift in balance between various T cell sub-
sets in IL1rn–/–Tlr2–/– mice characterized by reduced Th2 and Treg 
markers in spleen and locally within the joint and a seemingly 
enhanced Th1 marker in the joint. Consistently, IL1rn–/–Tlr2–/– T 
cells produced markedly higher amounts of IFN-γ upon general 
and CD3-specific stimulations. Recent findings identified IL-17 as 
a crucial disease-promoting factor in autoimmune disorders and 
showed an inhibitory effect of IFN-γ on Th17 development from 
naive T cells (42, 43); however, IL-17 production by effector and 
memory Th17 cells in the presence of IL-23 was not inhibited by 
IFN-γ. Therefore, in Tlr2–/– mice, where TLR4 and IL-23 pathways 
are intact, committed Th17 cells are expected to be resistant to 
suppression by IFN-γ. Interestingly, IL-17 production also repeat-
edly tended to be higher in IL1rn–/–Tlr2–/– T cells, despite similar 
Th17 cell number on FACS analysis. Very recently, the presence of 
a new T cell subtype producing both IFN-γ and IL-17, with more 
pathogenic characteristics compared with cells only producing 
IL-17, has been described in experimental autoimmune encepha-
lomyelitis (44). The presence of a similar “Th1/Th17” subset has 
also been demonstrated in the gut of patients with Crohn disease 
(45). Therefore, IL-17 and IFN-γ in Tlr2–/– mice might theoretically 
have been produced by the same cell population.
An effect on the Treg population in IL1rn–/–Tlr2–/– animals was 
confirmed by the significant reduction in the expression of the 
transcription factor Foxp3. Foxp3 is considered the most specific 
marker for Tregs, and its expression directly correlates with the 
suppressor activity of these cells, irrespective of CD25 expression 
(46, 47). Attenuated Foxp3 expression abrogates the immune-sup-
pressive, but not hypoproliferative, activities of Tregs and results 
in an aggressive autoimmune syndrome (48). TLR2 deficiency in 
IL1rn–/– mice led to less Foxp3 expression and reduced suppressive 
activity of these cells (Figure 4). Furthermore, expression of TGF-β1 
was partially reduced in Tlr2–/– spleen and synovium. TGF-β plays 
a complex role in T cell differentiation: in the absence of IL-6, it 
promotes the lineage commitment of naive T cells toward Tregs, 
while in the presence of IL-6, it promotes skewing of naive T cells 
toward the Th17 phenotype (49–52). In IL1rn–/– mice, the develop-
ment of neither Tregs nor Th17 cells was affected, since the num-
ber of both cell subsets remained unaltered. Alternatively, TGF-β 
is also produced by some Tregs and is one of the mechanisms of 
the suppressive function of these cells (53). In this context, lower 
TGF-β expression is in line with reduced Foxp3 expression and 
defective function of Tregs in Tlr2–/– mice; however, whether the 
reduced Treg function in these mice is a consequence of lower 
TGF-β production requires further investigation. The major func-
tion of Tregs is to inhibit other T cells from mounting an immune 
attack against self components and to prevent autoimmunity (54, 
55). Therefore, the exaggerated autoimmune arthritis in Tlr2–/– 
animals is a net result of reduced suppressive Treg function and 
enhanced IFN-γ–producing Th1 cells.
Tlr4-deficient IL1rn–/– mice, in contrast to Tlr2–/– animals, were 
protected against severe arthritis and long-term joint destruction. 
We demonstrate here that TLR4 promotes joint inflammation and 
both cartilage and bone destruction by driving the highly pathogen-
ic Th17 cells through induction of IL-1 and IL-23. Both CD4+ and 
CD4– (CD8+) IL-17–expressing cells were present in IL1rn–/– mice 
and were reduced upon Tlr4 deficiency. Therefore, both subpopula-
tions are considered to contribute to IL-17 production in IL1rn–/– 
mice. Inhibition of IL-1 blocked TLR4-mediated IL-17 production. 
IL-1β promotes, together with TNF-α, Th17 cell commitment from 
naive T cells, a process principally driven by IL-6 and TGF-β (49–51). 
Conditioned medium of TLR4-stimulated DCs has been shown to 
replace IL-6, IL-1β, and TNF-α in Th17 cell differentiation (51). In 
IL1rn–deficient coculture of APCs and T cells, IL-1 contributes to 
approximately 70% of IL-17 production (Figure 6E). The remaining 
IL-17 production is attributable to other LPS-induced cytokines 
produced by APCs, in particular IL-6. IL-23 by itself does not con-
tribute to Th17 differentiation; however, since the presence of 
already differentiated Th17 cells in the splenic cell culture of IL1rn–/– 
mice is presumable, LPS-induced IL-23 might also be involved by 
favoring the expansion and maintenance of these cells. IL-1 and 
IL-17 determine the inflammatory and destructive character of sev-
eral experimental models of arthritis (56–58). Furthermore, IL-17 is 
expressed in synovial sublining of RA patients (59) and inhibits col-
lagen synthesis and bone formation in synovium and bone explants 
of RA patients (60). Therefore, the function of TLR4 upstream of 
IL-1 and IL-17 might have important consequences for the treat-
ment of RA. Our previous studies emphasized the beneficial effects 
of specific TLR4 inhibition using a TLR4 antagonist in both col-
lagen-induced and IL1rn–/– arthritis (61).
The exact source of TLR ligands contributing to the modulation 
of arthritis is not clear. Enhanced IFN-γ production in Tlr2–/– mice 
and reduced IL-17 production in Tlr4–/– mice could be detected 
before any visible joint inflammation. This suggests that TLR 
ligands of microbial origin, not the endogenous ligands, are pos-
sibly involved in this phase. On the other hand, the similar disease 
incidence and the more pronounced suppression of disease sever-
ity in Tlr4–/– compared with Tlr4+/+ mice during the chronic late 
phase of arthritis suggest the involvement of endogenous TLR4 
ligands generated by inflammation and tissue damage. Several 
endogenous ligands have been described for both TLR2 and TLR4 
(4, 62, 63); however, in some pathologic situations, such as isch-
emia/reperfusion injury or hemorrhagic shock, only TLR4, but 
not TLR2, has been found to sense tissue damage (64–66). In the 
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present study, we show that synovial fluid of RA patients contains 
ligands capable of activating TLR4 on HEK293 cells. Inhibition 
of the spontaneous production of proinflammatory cytokines by 
synovial tissue of RA patients using a TLR4 antagonist underlines 
the clinical relevance of TLR4 activation in RA. TLR4 is mainly 
expressed on APCs, and its activation indirectly modulates Th17 
cells through induction of proinflammatory cytokines such as 
IL-1 and IL-6. TLR4 expression on T cells has also been demon-
strated; however, direct TLR4 stimulation of naive T cells does not 
induce Th17 cell differentiation (51). The contribution of TLR2 in 
IL1rn–/– arthritis is more likely to be a direct effect on T cells, since 
Tregs express functional TLR2, stimulation of which affects the 
expansion and function of these cells (15, 16) (Figure 4). Another 
remarkable point concerning the difference in regulation of arthri-
tis by TLR2 and TLR4 is that the Th1 profile with high IFN-γ lev-
els in Tlr2–/– mice did not aggravate cartilage destruction, whereas 
IL-17 clearly determined the severity of cartilage destruction as 
indicated by less cartilage damage in Tlr4–/– mice.
The differential and complex roles of TLR2 and TLR4 in defin-
ing the cytokine environment and T cell differentiation have great 
implications for future interventions in (auto)immune disorders. 
Considering the dual role of TLR2, therapeutic interventions on 
TLR2 still seem complicated and would warrant additional stud-
ies. In comparison with TLR2, TLR4 appears to be a more interest-
ing target, because it consistently plays a proinflammatory role 
and will probably be easier to interfere with. Further focus on the 
nature of TLR ligands and the kinetics of TLR-mediating immune 
regulation in distinct disease conditions is of high importance.
Methods
Animals. WT BALB/c mice were purchased from Charles River Laboratories. 
IL1rn–/– mice on a BALB/c background were generated as described previ-
ously (67). Tlr2–/– mice were on a C57BL/6 background, and Tlr4–/– and 
Tlr9–/– mice were backcrossed from C57BL/6 backgrounds onto BALB/c for 
5 generations. We crossed the mice (further) onto the arthritis-susceptible 
strain BALB/c mice until they were backcrossed for at least 8 generations. 
Subsequently, IL1rn–/– (Tlr+/+) and Tlr–/– (IL1rn+/+) mice were crossed, and 
offspring heterozygous for both IL-1Rn and each TLR were intercrossed to 
obtain homozygous IL1rn–/– mice that were either Tlr+/+ or Tlr–/–. The mice 
were housed in filter-top cages, and water and food were provided ad libi-
tum. Germ-free mice were housed in isolators under controlled environ-
mental and nutritional conditions. Lactobacillus bifidus was introduced into 
the germ-free animals at the age of 11 weeks by pouring 10 ml of the pure 
broth cultures in 10A medium (developed for selection of Lactobacilli) on 
the food as described previously (37). Age- and sex-matched littermates 
were used in all experiments. Animal studies were approved by the Institu-
tional Review Board of Radboud University Nijmegen Medical Centre and 
were performed according to the appropriate codes of practice.
Treatment of animals and clinical evaluation of arthritis. For in vivo TLR stim-
ulation, 6-week-old IL1rn–/– mice without arthritis were treated using a sin-
gle i.p. injection of the TLR2 ligand Pam3Cys (4 mg/kg body weight; EMC 
Microcollections) or the TLR4 ligand LPS (400 μg/kg; Sigma-Aldrich). 
Control mice received 0.2 ml sterile saline.
Development of arthritis was macroscopically scored using an arbitrary 
scoring system as follows: 0, no redness and swelling; 0.25, slight redness; 
0.5, slight redness and swelling; 0.75–1, mild redness and swelling; 1.25–1.5, 
moderate redness and swelling; 1.75–2, severe redness and swelling. Only 
the hind joints were scored, as forepaws developed arthritis very seldom.
Histology. For histological assessment of arthritis, total ankle joints from 
15-week-old mice were isolated and fixed for 4 days in 4% formaldehyde, 
then decalcified in 5% formic acid and embedded in paraffin. Tissue sections 
of 7 μm were stained using H&E to study the inflammatory cell influx and 
chondrocyte death or using safranin O to determine proteoglycan depletion 
and cartilage and bone destruction. Each parameter was scored on a scale 
from 0 to 3 by 2 independent observers in a blinded manner. At least 4 junc-
tions per tissue section and 4 sections per ankle joint were scored.
Generation and maturation of bone marrow–derived DCs. Bone marrow cells 
were isolated from 6- to 8-week-old IL1rn–/– mice without arthritis and cul-
tured for 9 days with 3 ng/ml GM-CSF (R&D). The DC phenotype was con-
trolled by measuring the CD11c expression on FACS using anti-CD11c–APC 
antibodies (BD Biosciences — Pharmingen). For DC maturation and IL-23 
production, 1 × 106 immature DCs were incubated with 100 ng/ml purified 
E. coli LPS, 100 ng/ml Pam3Cys or the Jonuleit cocktail (68) consisting of 
IL-1β (25 ng/ml), TNF-α (25 ng/ml), IL-6 (100 ng/ml), and PGE2 (1 μg/ml) 
for 24 hours. DC maturation was determined by measuring the upregulation 
of MHC class II and CD86 markers using anti-MHCII–FITC (BMA Biomedi-
cals) and anti-CD86–PE (BD Biosciences — Pharmingen) FACS antibodies.
Isolation, culture, and stimulation of lymphocytes. Spleens and popliteal and 
inguinal lymph nodes were isolated and disrupted. Erythrocytes in spleens 
were lysed. Then, the cell suspension was enriched for T cells by allowing 
APCs to adhere to plastic culture flasks for 45 minutes. For APC–T cell 
cocultures, total splenocytes were used without performing any adherence 
step. For some experiments described in Results, T cells were isolated using 
the magnetic cell sorting (MACS) technique (Miltenyi Biotec) following 
the manufacturer’s guidelines prior to stimulation. Cells were cultured in 
RPMI-1640 (Gibco; Invitrogen) supplemented with 5% FCS, 1 mM pyruvate, 
and 50 mg/l gentamicin at 37°C, 5% CO2 with the following stimulations: 
plate-coated anti-CD3 (2 μg/ml or 0.5 μg/well as indicated in Figure leg-
ends; R&D), anti-CD28 (2 μg/ml; BD Biosciences), PMA (50 ng/ml; Sigma-
Aldrich), ionomycin (1 μg/ml; Sigma-Aldrich), the Golgi-traffic inhibitor 
brefeldin (1 μl/ml; BD Biosciences), Pam3Cys (100 ng/ml; EMC Microcollec-
tions), and LPS (200 ng/ml, double-purified using the phenol-water extrac-
tion method at our laboratory; Sigma-Aldrich). For IL-1 blocking, polyclonal 
rabbit anti-mouse IL-1α and IL-1β antibodies (69) were used in combi-
nation. Final concentrations were 20 and 80 μg/ml for IL-1α and IL-1β, 
respectively. Anti–IL-1 serum contained 10 mg/ml purified antibodies, 
and 1 μg of these antibodies was shown to neutralize up to 100 pg IL-1 in 
the NOB-1 bioassay (70). Normal rabbit serum (NRS) was used as control. 
Anti–IL-1 sera and NRS were added to the cells shortly before addition of 
LPS. Incubation time was 72 hours for anti-CD3 and anti-CD28; 5 hours for 
PMA, ionomycin, and brefeldin; and 24 hours for Pam3Cys and LPS.
T cell proliferation and suppression assay. Splenic MACS-isolated CD4+CD25– 
Teffs (50,000 cells/well) were stimulated with 1 μg/ml anti-CD3, 2 μg/ml 
concanavalin A, or 60 IU/ml IL-6 (negative control) in the presence of 
50,000/well irradiated (30 Gy) CD4– cells as APCs. After 3 days, prolif-
eration was measured by [3H]thymidine incorporation. For suppression 
assays, cells were incubated with anti-CD3 and APCs in the presence of 
titrated numbers of Tregs (CD4+CD25+). Percentage of suppression was 
calculated relative to the cultures without Tregs.
Measurement of cytokines. Cytokine concentrations (except those of IL-23) 
in culture supernatants were determined using Luminex multianalyte 
technology. The Bioplex system in combination with multiplex cytokine 
kits (Bio-Rad) was used. IL-23 concentrations were measured using ELISA 
(eBioscience) following the manufacturer’s instructions.
FACS analysis of T cells. Th17 cells in spleen and lymph nodes were stained 
using anti-CD4-APC, then washed with FACS buffer (PBS plus 1% BSA) 
and fixed in PBS containing 2% paraformaldehyde. Subsequently, cells were 
stained with anti–IL-17–PE in FACS buffer containing 0.1% saponin. Tregs 
in whole blood and spleen, in which erythrocytes were lysed, were stained 
with anti-CD4–APC and anti-CD25–FITC. Then, cells were fixed and 
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permeabilized using Fix/Perm buffer (eBioscience) and stained with anti-
Foxp3–PE. An appropriate isotype-matched control antibody was used in 
all FACS analyses. All antibodies were from BD Biosciences — Pharmingen 
except anti-Foxp3 (eBioscience). Cells were analyzed on a FACSCalibur flow 
cytometer using CellQuest software (BD Biosciences — Pharmingen).
Isolation of RNA from spleen and synovial biopsies. Six-week-old mice without 
arthritis were sacrificed by cervical dislocation, and spleens were isolated 
and stored separately in liquid N2 until RNA isolation (n = 4 per group). 
Synovial biopsies were isolated from the ankle joints with various degrees 
of macroscopic inflammation by dissecting synovium around and between 
ankle bones using microscissors. Synovium samples with the same inflam-
mation score (5–6 joints each) were pooled within each group and kept 
separately to avoid any influence of differences in the degree of inflamma-
tion on mRNA expression of the genes of interest.
Total RNA was isolated in 1 ml TRIzol (Sigma-Aldrich), then precipi-
tated with isopropanol, washed with 70% ethanol, and dissolved in water. 
RNA was treated with DNase and subsequently reverse transcribed into 
cDNA using oligo-dT primers and MMLV reverse transcriptase.
Quantitative real-time PCR. Quantitative real-time PCR was performed 
using the ABI Prism 7000 Sequence Detection System (Applied Biosys-
tems) for quantification with SYBR Green and melting curve analysis. 
Primer sequences were as follows: for GAPDH (housekeeping gene), 5′-
GGCAAATTCAACGGCACA-3′ (forward) and 5′-GTTAGTGGGGTCTC-
GCTCTG-3′ (reverse); for IL-23p19, 5′-CCAGCGGGACATATGAATC-
TACT-3′ (forward) and 5′-CTTGTGGGTCACAACCATCTTC-3′ (reverse); 
for IL-17A, 5′-CAGGACGCGCAAACATGA-3′ (forward) and 5′-GCAA-
CAGCATCAGAGACACAGAT-3′ (reverse); for TGF-β1, 5′-GCAGTGGCT-
GAACCAAGGA-3′ (forward) and 5′-AAGAGCAGTGAGCGCTGAATC-3′ 
(reverse); for T-bet, 5′-CAACAACCCCTTTGGCAAAG-3′ (forward) and 
5′-TCCCCCAAGCAGTTGACAGT-3′ (reverse); for GATA3, 5′-AGAACC-
GGCCCCTTATCAA-3′ (forward) and 5′-AGTTCGCGCAGGATGTCC-3′ 
(reverse); for Foxp3, 5′-AGGAGAAGCTGGGAGCTATGC-3′ (forward) and 
5′-GGTGGCTACGATTGCCAGCAA-3′ (reverse).
PCR conditions were as follows: 2 minutes at 50°C and 10 minutes at 95°C, 
followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C, with data 
collection during the last 30 seconds. For all PCRs, SYBR Green Master Mix 
(Applied Biosystems) was used in the reaction. Primer concentrations were 
300 nM. The Ct value of the gene of interest was corrected for the Ct of the 
reference gene GAPDH to obtain the ΔCt. Relative mRNA expression was cal-
culated by 2 to the power of –ΔCt. Quantitative PCR analysis for each sample 
was performed in duplicate, and melting curves were run for each PCR.
Assessment of endogenous TLR4 ligands in synovial fluid and synovial tissue 
of RA patients. HEK293 and HEK293-TLR4 cells were purchased from 
InvivoGen and cultured according to the manufacturer’s guidelines. 
For stimulations, 5 × 104 cells/well were used in flat-bottom, 96-wells 
plates. HEK293-TLR4 cells were stimulated with PMA (50 ng/ml; Sigma-
Aldrich), hIL-1β and hTNF-α (both 20 ng/ml; R&D), Pam3Cys (10 μg/ml; 
ECM Microcollections), Poly(I:C) (25 μg/ml; InvivoGen), LPS (10, 100, 
and 1000 ng/ml; Sigma-Aldrich), and Gardiquimod (1 μg/ml; Invivogen) 
for 24 hours, and IL-8 was measured in culture supernatants. For stimu-
lation with synovial fluid of RA patients, 10 μl synovial fluid was added 
into 200 μl culture medium containing 100 ng/ml TNF blocker (Enbrel; 
Amgen). IL-8 was measured in culture supernatants, and stimulation 
index over the medium control was calculated. Spontaneous production 
of cytokines was measured upon 24 hours ex vivo culture of RA synovial 
biopsies (3 mm in diameter) incubated with or without 10 μg/ml Barton-
ella quintana LPS as TLR4 antagonist (61). Assays were performed in trip-
licate. All patients provided informed consent, and the Medical Ethics 
Committee of Radboud University Medical Centre Nijmegen approved 
the study protocol.
Statistics. Group measures are expressed as mean ± SEM unless otherwise 
indicated. The statistical significance of differences between experimental 
groups was assessed using the Mann-Whitney U test performed on Graph-
Pad Prism 4.0 software (GraphPad Software Inc.). P values of 0.05 or less 
were considered significant.
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